Sign In
Buy MYOV
$26.98
+0 (+0%)
At Close: Jun 08, 2023
Myovant Sciences reports Q4 EPS (96c), consensus (82c) MYOV
01:33pm, Monday, 10'th Feb 2020
Myovant Sciences reports Q4 EPS (96c), consensus (82c) MYOV
- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter.
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Resultsfor Third Fiscal Quarter Ended December 31, 2019
01:30pm, Monday, 10'th Feb 2020
- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer...
Myovant Sciences (MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced that the Phase 3 LIBERTY open-label extension study of
Myovant Sciences (NYSE:MYOV) Earns Neutral Rating from Analysts at Citigroup
10:42am, Wednesday, 05'th Feb 2020
Citigroup started coverage on shares of Myovant Sciences (NYSE:MYOV) in a research note issued to investors on Sunday morning, BenzingaRatingsTable reports. The brokerage issued a neutral rating and a
Reviewing Q BioMed (OTCMKTS:QBIO) and Myovant Sciences (OTCMKTS:MYOV)
08:46am, Wednesday, 05'th Feb 2020
Q BioMed (OTCMKTS:QBIO) and Myovant Sciences (NYSE:MYOV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their ris
Myovant Sciences: A Promising Investment Opportunity In 2020
09:15am, Tuesday, 04'th Feb 2020
Relugolix combination regimen is targeting an underserved opportunity in uterine fibroids indication. Relugolix monotherapy can prove to be a game changer in an
Former Genentech exec looks to replicate that 'magical time' with new biotech model
09:39pm, Monday, 03'rd Feb 2020
Myrtle Potter wants Sumitovant to "keep thinking about complex problems and stay scrappy and stay focused on the programs that make a difference for patients."
Bluebird up 2% premarket on two new bullish calls
01:34pm, Monday, 03'rd Feb 2020
Bluebird bio (NASDAQ:BLUE) initiated with Buy rating and $120 (56% upside) price target at Bank of America. Upgraded to Outperform with a $100 price target at Evercore ISI. Shares up 2% premarket.Ce
Myovant Sciences resumed with a Neutral from Buy at Citi MYOV
11:25am, Monday, 03'rd Feb 2020
Myovant Sciences resumed with a Neutral from Buy at Citi Citi MYOV
Myovant Sciences: Bull And Bear Cases And Investment Decision
10:46am, Monday, 03'rd Feb 2020
I estimate >75% probability of success for SPIRIT 2 and 2 trials for Relugolix in treating endometriosis-associated pain (data in H1 2020). Recent Phase 3 resul
Myovant Sciences Ltd (NYSE:MYOV) Forecasted to Post FY2020 Earnings of ($3.17) Per Share
09:18am, Friday, 31'st Jan 2020
Myovant Sciences Ltd (NYSE:MYOV) – Equities research analysts at Svb Leerink increased their FY2020 EPS estimates for Myovant Sciences in a research note issued to investors on Monday, January 27th.
The "Heavy Menstrual Bleeding (HMB) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
Heavy Menstrual Bleeding (HMB) Market Analysis and Forecast 2017-2028
12:50pm, Monday, 27'th Jan 2020
Dublin, Jan. 27, 2020 -- The "Heavy Menstrual Bleeding (HMB) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to.
CEOs of Women’s Health Companies Fight to Open Investment Floodgates
11:00am, Wednesday, 22'nd Jan 2020
Talking about sex with potential investors? For EvoFem Biosciences CEO Saundra Pelletier, it’s the first item on the docket. Her company recently
